Nature's Miracle Holdingの空売り状況は、投資家がNature's Miracle Holdingの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Nature's Miracle Holding (OTC:NMHI) 株価情報, 空売り情報

Nature's Miracle Holding

Nature's Miracle Holding Inc is a growing agriculture technology company providing Controlled Environment Agriculture (CEA) hardware products to growers in the CEA industry setting in North America. It provides hardware to design, build, and operate various indoor growing settings, including greenhouses and indoor growing spaces. Its products include Horticultural Lighting, Irrigation Systems, Power Distribution Systems, Climate Control Systems, Disinfection Systems, and Materials and Equipment. The company derives all of its revenue from the USA.

NATURE'S MIRACLE HLDG INC by Nature's Miracle Holding Inc.

Nature's Miracle Holding Inc

Nature's Miracle Holding Inc Warrants (08/03/2029)

Evercore ISI Group analyst Michael Binetti maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Outperform and lowers the price target from $400 to $320.

News

Price Target

Analyst Ratings

LULU

Evercore ISI Group Maintains Outperform on Lululemon Athletica, Lowers Price Target to $320

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">down 4.5% on the week</a> but continues to attract optimism from traders and analysts, especially after a dormant whale reappeared after three years.
According to Lookonchain, wallet address 0x6E45 <a href="https://x.com/lookonchain/status/1930841724647362561">transferred</a> 100.45 billion SHIB (worth $1.21 million) to Binance after three years of inactivity. The whale netted a $311,000 profit, though at SHIB's all-time high, the same position could've delivered over $2.7 million in gains.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td> $0.00001273</td>
<td>$7.5 billion</td>
<td>-0.5%&nbsp;</td>
<td>&nbsp;-4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td> $0.1829</td>
<td>$2.13 billion</td>
<td>-3.7%&nbsp;</td>
<td>-9.6%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td> $0.00001141</td>
<td>$4.8 billion </td>
<td>-1.6%&nbsp;</td>
<td>-11.4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Analysts at TheCryptoBasic <a href="https://x.com/thecryptobasic/status/1930622580639113648">suggest</a> SHIB could reach $0.000224 by June 2030 if it manages a 5% average monthly growth—a 1,766% surge from its current price of $0.00001270. 
That would push SHIB's market cap to around $132 billion, assuming no major supply dilution or pullbacks.
Other platforms like Telegaon, Changelly, and several crypto analysts also forecast a similar target between 2025 and 2031, though all emphasize that such consistent growth is rare in the volatile crypto space.
Statistics: Whale Alert <a href="https://x.com/whale_alert/status/1930750500229542238">flagged</a> a massive 3.6 trillion SHIB transfer to Coinbase Institutional, fueling speculation about potential strategic moves or sentiment shifts.
IntoTheBlock data shows Shiba Inu large transaction volume and daily active addresses expanded by 58.3% and 2.4% respectively in a single day. 
Transactions greater than $100,000 are up from 56 to 522.
Shibariumscan data shows daily transactions up to 710,000 from from 631,800 the prior day.
Shibarium new accounts skyrocketed from 86 as of June 5 to 1,024 as of June 6.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45745042/shiba-inu-burn-rate-soars-by-2408-is-a-breakout-imminent">Shiba Inu Burn Rate Soars By 2,408%: Is A Breakout Imminent?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Slides 4.5% On The Week: Why Is It Going Down?

Evercore ISI Group analyst Amit Daryanani maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a In-Line and lowers the price target from $82 to $75.

CIEN

Evercore ISI Group Maintains In-Line on Ciena, Lowers Price Target to $75

Evercore ISI Group analyst Robert Ottenstein maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a In-Line and lowers the price target from $38 to $30.

BF/B

Evercore ISI Group Maintains In-Line on Brown-Forman, Lowers Price Target to $30

Evercore ISI Group analyst Mark Lipacis maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Outperform and raises the price target from $267 to $304.

AVGO

Evercore ISI Group Maintains Outperform on Broadcom, Raises Price Target to $304

Rio Tinto Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) disclosed on Thursday that it has officially inaugurated its newest <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">iron ore mine, Western Range</a>.
The Western Range is one of several replacement projects, collectively boasting an annual capacity of approximately 130 million tonnes.
The mine is designed to produce up to 25 million tonnes of iron ore annually, and <a target="_blank" href="https://www.businesswire.com/news/home/20250605488902/en/Rio-Tinto-and-Baowu-open-Western-Range-iron-ore-mine-in-the-Pilbara-with-Yinhawangka-Traditional-Owners" rel="noreferrer noopener">it </a>has the potential to sustain the existing Paraburdoo mining hub for as long as two decades.
The $2 billion project, a joint venture between Rio Tinto (54%) and Baowu (46%), was finished on time and within budget.
Also Read: <a href="https://www.benzinga.com/news/legal/25/05/45640179/supreme-court-rejects-appeal-allows-rio-tinto-mine-to-proceed-on-tonto-forest-sacred-land" target="_blank" rel="noreferrer noopener">Supreme Court Rejects Appeal, Allows Rio Tinto Mine To Proceed On Tonto Forest Sacred Land</a>
This endeavor included constructing a primary crusher and an 18-kilometer conveyor system that connects to the existing Paraburdoo processing plant.
The new mine ensures stability for Paraburdoo&#8217;s workforce of over 880 residential and FIFO (fly-in/fly-out) employees.
The Western Range project is notable as Rio Tinto&#8217;s inaugural endeavor to incorporate a co-designed Social, Cultural and Heritage Management Plan (SCHMP) alongside the Yinhawangka Traditional Owners.
Rio Tinto Chief Executive Jakob Stausholm said, "Opening Western Range is an important step in Rio Tinto's extension plans in the Pilbara and ensures the longevity of one of our oldest mining hubs, Paraburdoo, which began operating in 1972.&#8221;
"Partnering with Baowu ensures our biggest customer directly benefits with a consistent, dedicated supply of Rio Tinto's world leading Pilbara Blend iron ore."
Notably, over the next three years (2025-2027), Rio Tinto anticipates investing more than $13 billion in new mines, plants, and equipment.
This follows an investment of approximately $8.5 billion in the Pilbara during the preceding three-year period (2022-2024).
In May, the company disclosed that Stausholm will step down from his role later this year and disclosed 2029 bauxite expansion in Queensland with a feasibility study for a 20 million tonne <a href="https://www.benzinga.com/25/05/45564513/rio-tinto-ceo-jakob-stausholm-to-step-down-launches-19b-bauxite-expansion-plan" target="_blank" rel="noreferrer noopener">boost to Weipa output</a>.
Price Action: RIO shares are down 0.57% at $58.89 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/global/25/05/45513934/rio-tinto-expands-lithium-push-with-900-million-maricunga-deal" target="_blank" rel="noreferrer noopener">Rio Tinto Expands Lithium Push With $900 Million Maricunga Deal</a></li>
</ul>
Photo: Shutterstock

Equities

Mid Cap

Rio Tinto Opens $2B Pilbara Iron Ore Mine With China's Baowu

Truist Securities analyst Bill Chappell maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Buy and raises the price target from $125 to $130.

Truist Securities Maintains Buy on e.l.f. Beauty, Raises Price Target to $130

Truist Securities analyst Patrick Scholes maintains Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Buy and lowers the price target from $247 to $244.

Truist Securities Maintains Buy on Vail Resorts, Lowers Price Target to $244

Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) has outperformed the market over the past 5 years by 13.46% on an annualized basis producing an average annual return of 26.78%. Currently, Teck Resources has a market capitalization of $19.29 billion. 
Buying $1000 In TECK: If an investor had bought $1000 of TECK stock 5 years ago, it would be worth $3,159.87 today based on a price of $38.74 for TECK at the time of writing.
<h3>Teck Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749222912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TECK

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

The U.S. has some of the world's most well-known and profitable stock exchanges, but they aren't the only game in town. Many nations have well-run, lucrative stock exchanges that offer compelling investment opportunities. Some are making investors so much money that<a href="https://www.msn.com/en-us/money/markets/jim-cramer-says-us-stock-market-is-hideously-underperforming-compared-to-europe/ar-AA1FsyLX?ocid=winp1taskbar&amp;cvid=2210a02246f947aaf8b4901ea14290a4&amp;ei=22"> CNBC's Jim Cramer</a> recently slammed U.S. exchanges for "hideously underperforming" compared to their rivals. Is this the beginning of a global shift or just a blip on the radar?
"The money keeps going into these European stocks, and it's rather amazing,"<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45667369/jim-cramer-praises-defense-contractor-as-great-deal-says-buy-interactive-brokers-too">Cramer</a> told CNBC's "<a href="https://www.cnbc.com/2025/05/25/us-vs-european-stocks-here-is-where-jim-cramer-comes-down-on-the-debate.html">Squawk on the Street</a>." The recent trend of high-performing European exchanges traces back to President <a href="https://www.benzinga.com/news/topics/25/05/45708977/trump-doubles-steel-tariffs-to-50-saying-it-will-secure-american-jobs-backs-us-steels-takeover-by-japans-nippon">Donald Trump's tariffs</a>, which have roiled America's stock and bond markets. According to CNBC, Germany's DAX is up 19% this year.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
By contrast, CNBC noted that the S&amp;P 500 is only up 1% in 2025. That doesn't necessarily mean it's time to abandon the S&amp;P 500. No one can deny it has delivered incredible returns for investors, especially over the last decade. However, the index's strengths conceal a big potential weakness. The S&amp;P 500's gains have mostly been in the tech sector, which dominates the Magnificent Seven stocks at the top of the index.
The tech sector depends heavily on components and raw materials from China, and those products are now subject to the Trump administration's tariffs. Although negotiations between Trump and President Xi Jinping are ongoing, the uncertainty surrounding the long-term picture has rattled investor confidence in the U.S. tech sector.&nbsp;
The uncertainty surrounding big tech is not the only headwind for U.S. stocks. U.S. debt is also a concern for global investors and credit ratings agencies. Moody's downgraded U.S. credit rating only a few hours after Trump proposed a 50% tariff on EU goods. That coincided with a jump in bond yields, which caused investors worldwide to cool on the U.S. market.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
Adverse market conditions and instability are not unique experiences on U.S. exchanges. They've happened before, but investors tended to hedge their bets by making commodities trades or alternative investments on U.S.-based exchanges. The game is very different now, and ironically, much of the change is due to big tech's influence on global commerce.
Investing on foreign exchanges used to be complicated. Now, all it takes is an internet connection and a few clicks on a mobile phone or computer.&nbsp; "What's happening that didn't happen then is there is an alternative," said Cramer. Increasingly, investors are turning to Europe. CNBC notes that many European stocks offer better price-to-value ratios and stronger returns. That's in addition to the ECB's more investor-friendly interest rate policy.
It's not just individual investors moving their money to Europe. CNBC also sighted research&nbsp; from investment firm KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), which said, "Many [chief investment officers] are considering moving assets out of the United States towards other parts of the world." The fact that large institutional investors are also moving their money to Europe means it's more than just a question of convenience.
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Europe offers solid options if you're an investor searching for an alternative to U.S. exchanges. Cramer believes Europe is "safer and more predictable" and says it "can continue to climb given the momentum." Despite that, the recent productivity in the European markets doesn't necessarily mean a permanent power shift is in the cards.
CNBC noted that the U.S. market is still twice as large as Europe's, and still has quality options for investors. It may seem counterintuitive, but moments of market instability often carry the best opportunities for investors to buy stocks with upside at a discounted price. Despite his criticism, Cramer still believes in the U.S. market and its long-term potential. "There are tons of stocks I would like to buy if the prices come down," he said.
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

Personal Finance

Jim Cramer Slams U.S. Stock Market For 'Hideously Underperforming' In Comparison To European Exchanges

Truist Securities analyst Bill Chappell maintains Scotts Miracle Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) with a Buy and raises the price target from $70 to $75.

Truist Securities Maintains Buy on Scotts Miracle Gro, Raises Price Target to $75

JP Morgan analyst Mark Murphy maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Neutral and lowers the price target from $81 to $77.

DOCU

JP Morgan Maintains Neutral on Docusign, Lowers Price Target to $77

Goldman Sachs analyst Mark Delaney maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and lowers the price target from $295 to $285.

TSLA

Goldman Sachs Maintains Neutral on Tesla, Lowers Price Target to $285

Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) announced it will present five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. 
Among them is new data from the INTEGUMENT-OLE study, showing that investigational ZORYVE cream 0.05% is safe and effective long-term for children aged 2 to 5 with atopic dermatitis (AD). By Week 4, 30.2% of participants (170 children) who achieved clear skin (vIGA-AD score of 0) transitioned to proactive, twice-weekly treatment.
For participants who switched to twice-weekly application, the median duration of disease control (maintaining vIGA-AD of clear or almost clear with adequate control of signs and symptoms on the twice-weekly schedule application) was 238 days (34 weeks), consistent with the 281 days observed for adults and children down to age 6 who used twice-weekly dosing.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44364298/whats-going-on-with-arcutis-biotherapeutics-stock-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Arcutis Biotherapeutics Stock Monday?</a>
Additional data from Arcutis Biotherapeutics shows that both ZORYVE cream 0.15% and investigational 0.05% significantly reduced signs, symptoms, and itch in individuals 2 years and older with atopic dermatitis (AD). Arcutis confirmed that these improvements — reduced body surface area (BSA) affected and clinically meaningful itch relief — were sustained with long-term use, including for those on twice-weekly maintenance therapy.
Key outcomes:
<ul class="wp-block-list">
<li>vIGA-AD 0/1 (clear or almost clear) was achieved by: 
<ul class="wp-block-list">
<li>32.7% of participants aged 6+ and 28.8% of those aged 2–5 at Week 4</li>
<li>Increasing to 55.7% and 63.1%, respectively, by Week 52</li>
</ul>
</li>
<li>Clinically meaningful itch reduction (≥4-point WI-NRS drop): 
<ul class="wp-block-list">
<li>30.9% (6+) and 41.2% (2–5) after 4 weeks</li>
<li>Rising to 55.3% and 60.7%, respectively, after 52–56 weeks</li>
</ul>
</li>
<li>By Week 52, 47.1% (6+) and 40.7% (2–5) had no or minimal itch (WI-NRS of 0 or 1)</li>
</ul>
The treatment was well tolerated, with low rates of treatment-related adverse events (4.7% for ages 6+ and 2.5% for ages 2–5), and minimal reports of application-site pain (0.5% and 0.7%, respectively).
Price Action: ARQT stock is up 2.59% at $13.86 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response" target="_blank" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

ARQT

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis

Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) reported better-than-expected earnings for the <a href="https://www.benzinga.com/quote/BRZE/earnings">first quarter on Thursday</a>.
The company posted quarterly earnings of 7 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $162.06 million which beat the analyst consensus estimate of $158.66 million.
Braze lowered its FY2026 adjusted EPS guidance from 31 cents to 35 cents, but raised its FY2026 sales outlook from $686.00 million-$691.00 million to $702.00 million-$706.00 million.
&#8220;We are off to a good start in fiscal year 2026, delivering strong revenue growth, profitability, and free cash flow in an ever-changing environment,&#8221; said Bill Magnuson, Cofounder and CEO of Braze. &#8220;I&#8217;m also excited to announce that Ed McDonnell will be joining Braze in July to lead all aspects of our global revenue operations. McDonnell has a strong track record of delivering results at high-growth public SaaS businesses, and we believe his extensive background in Software and Customer Engagement will further solidify Braze as the leading customer engagement platform and accelerate growth in the coming years.&#8221;
Braze shares dipped 12.6% to trade at $31.50 on Friday.
These analysts made changes to their price targets on Braze following earnings announcement.
<ul class="wp-block-list">
<li>Stephens &amp; Co. analyst Brett Huff maintained Braze with an Overweight rating and lowered the price target from $51 to $41.</li>
<li>UBS analyst Taylor McGinnis maintained Braze with a Buy rating and cut the price target from $51 to $48.</li>
<li>JMP Securities analyst Patrick Walravens reiterated Braze with a Market Outperform and maintained a $68 price target.</li>
</ul>
Considering buying BRZE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06111101/image-104-1024x584.png" alt="" class="wp-image-941444" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06111101/image-104-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06111101/image-104-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06111101/image-104-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06111101/image-104.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>

Earnings

Markets

BRZE

Braze Analysts Slash Their Forecasts After Q1 Earnings

<a href="https://www.bloomberg.com/news/articles/2025-06-06/deutsche-bank-is-exploring-stablecoins-and-tokenized-deposits?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-06/deutsche-bank-is-exploring-stablecoins-and-tokenized-deposits?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-06/deutsche-bank-is-exploring-stablecoins-and-tokenized-deposits?srnd=homepage-americas</a>

'Deutsche Bank Is Exploring Stablecoins and Tokenized Deposits' - Bloomberg News

JP Morgan analyst Andrea Teixeira maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Underweight and lowers the price target from $34 to $28.

JP Morgan Maintains Underweight on Brown-Forman, Lowers Price Target to $28

WIIM

AVAV

AeroVironment shares are trading higher after Baird maintained its Outperform rating on the stock and raised the price target from $146 to $210.

Truist Securities analyst Joel Fishbein maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Buy and raises the price target from $90 to $110.

RBRK

Truist Securities Maintains Buy on Rubrik, Raises Price Target to $110

JP Morgan analyst Pinjalim Bora maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Overweight and lowers the price target from $47 to $45.

Comments

Nature's Miracle Holding

空売り

Nature's Miracle Holding (OTC:NMHI) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル